Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (October 2017)
20 slides from Pyc Therapeutics's investor presentation, Oct 9, 2017
Slide 1: Phylogica Investor Presentation
For personal use only Phylogica (ASX:PYC) Investor Presentation By Stephanie Unwin (CEO) Dr Robert Hayes (CSO) October 2017
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: About Us
About Us For personal use only What Who are What do makes us we? we do? unique? Biotech platform Expand the reach of Our proprietary library of technology that biologic drugs to the cell-penetrating enhances a highly previously peptides coupled with potent class of undruggable our sophisticated biol
Slide 4: Experienced Management Team
Experienced Management Team For personal use only In mid 2017 Phylogica revitalised its management team with senior Pharma and commercial executives: Deep executive and Core Management Team commercial experience Highly seasoned pharmaceutical Executive at $3B energy utility; executive Ms Stephanie
Slide 5: Significant constraints in existing drug discovery approaches
Significant constraints in existing drug discovery approaches For personal use only The Our problem? solution? Drug discovery growth We can bring biologics stagnating as biologics into the cell, unlocking currently limited to the potential of these extracellular targets powerful drugs by (unable to
Slide 6: Key Investment Highlights
Key Investment Highlights For personal use only Phylogica has a unique selection of valuable assets … … huge potential market • Complex, rich Phylomer library – provides tremendous value and Addressing a large unmet market flexibility in either target identification or drug discovery need - 250B U
Slide 7: Financial details
Financial details For personal use only Phylogica (ASX:PYC) share price August Current share price: $0.045 2016 -2017 0.06 0.05 Shares on issue: 2.12Bn 0.04 0.03 Market Cap: $95.4M 0.02 0.01 0 Cash : $9.5M 7
Slide 8: About Phylogica's FPPs
About Phylogica’s proprietary cell penetrating peptides (FPPs), which escape the endosome, can deliver a diverse range For personal use only Phylogica’s FPPs of ‘biologic cargoes’ into cells, overcome existing challenges to drug delivery Phylogica’s FPP FPPs attach to “biologic cargoes” (i.e. such a
Slide 9: Best-in-class: Phylogica's FPP
Best-in-class: For personal use only 159-fold Phylogica’s FPP 37-fold 50 40 Problem we solve: conventional Cell Penetrating Drug Deliver Efficiency Peptides (CPPs) are mostly trapped within the 30 endosome inside cells (% +ve Cells) 20 Phylogica’s FPPs: • Enable the drug to penetrate cells and escap
Slide 10: Best-in-Class: Phylogica's FPP
Best-in-Class: Phylogica’s FPP For personal use only Phylogica’s existing FPPs have shown strong improvement potential Significant improvement • Initial attempts have yielded significant improvement • More potential exists: additional techniques could further improve FPP potency This further validat
Slide 11: FPPs deliver a diverse range and size of cargos
FPPs deliver a diverse range and size of cargos Conceptual stage Validated efficacious delivery For personal use only Example cargos, and targeted diseases, that can be delivered with FPPs Cargo class Example cargo Example disease Progress1 Cargo size Oligo nucleotide Morpholino Duchenne muscular dy
Slide 12: Building a comprehensive matrix of FPPs
Building a comprehensive matrix of FPPs Conceptual In vitro validation to target different cargoes and cell types In vivo validation For personal use only FPP01 validation matrix Oligo- Expand to Peptides Scaffolds Enzymes Antibodies nucleotide new cargoes Breast tumour Phylogica is validating FPP’s
Slide 13: Demonstrating platform capability - lead program iMyc
Demonstrating platform capability - lead program iMyc For personal use only How is What is What is iMyc Myc? iMyc? effective? Cell Growth • PYC’s iMyc (Myc inhibitor) • Current Gold Standard reduces over-expressed OmoMyc protein Myc Metabolism Myc in cells, effectively • OmoMyc has low potency Apopt
Slide 14: Phylogica adds value to customer drugs
Phylogica adds value to customer drugs For personal use only Typical drug DRUG PRECLINICAL CLINICAL FDA APPROVAL discovery process DISCOVERY (animal testing) (human trials) Typical 5 years 1.5 years 6 years 1-2 years Timelines Determination Drug safety & Drug safety & Regulatory Key of a suitable ef
Slide 15: Commercial opportunities
Commercial opportunities For personal use only Value proposition: Enhance existing drugs to address a massive 250B USD (CAGR 10.6%) market 2. Enhance 3. Reduce 1. Bring drugs properties of discovery to the right drugs (e.g., cycle time (by place (i.e., to improve dramatically intracellular therapeut
Slide 16: Partnering Strategy
Partnering Strategy For personal use only Helping customers add value to their … and partnering with academia to enhance existing drugs … the value of our library 16
Slide 17: Phylogica's flexible platform has enabled diverse partnerships
Phylogica’s flexible platform has enabled diverse partnerships For personal use only Cell specific Highly potent cargo Drug discovery Beyond human cells penetration delivery • Licensed a bespoke • Isolating Phylomers • Discovered peptides • Delivered bacterial peptide that can help kill which select
Slide 18: Commercial Strategy
Commercial For personal use only Strategy 2016 2017 2018 Scientific • Delivery to breast cancer, • Identified 13 additional potential • In vivo efficacy data spleen and bone marrow FPPs for diverse cargoes validation cells • Development and • Appointed high-calibre CEO, CSO • Automation and Operatio
Slide 19: Phylogica is laser-focused on three goals
Phylogica is laser-focused on three goals For personal use only Building platform • Deliver in vivo functional validation proof of concept • Demonstrate the improvement potential of Outcome: 1 across a range of existing FPPs target cargoes • Enrich and validate our library A validated, sought after
Slide 20: Thank you
For personal use only Thank you For more information contact Stephanie Unwin at stephanieu@phylogica.com